Broadly neutralizing antibodies (bNAbs) show potential to prevent human immunodeficiency virus (HIV-1) infection in humans. However, there are limited data on the antibody concentrations required to prevent infection. Clinical trials of bNAb prophylaxis have demonstrated partial efficacy, but the ...
The main barrier to HIV cure is a persistent reservoir of latently infected CD4+ T cells harboring replication-competent provirus that fuels rebound viremia upon antiretroviral therapy (ART) interruption. A leading approach to target this reservoir invol
Serum concentrations of all four SIV Env RhmAbs peaked 24 h after s.c. injection and then declined before the second administration (Fig.2eand Extended Data Fig.2). Median Cmax, Ctroughand half-life of each RhmAb in the three groups of RMs are shown in Table2. Half-lives were mostly...
英文: Antifibrinolytics reduced bleeding in clinical trials, but animal study findings were inconclusive.中文: 抗纤药在临床试验中减少出血,但在动物实验中是非结论性。英文: The jury found the evidence against the prisoner inconclusive and acquitted him.中文: 陪审团发现控告囚犯的罪证不确凿,所以释放了他...
In summary, despite the limited availability of clinical trials evaluating the effects of dietary interventions on gut microbiota and inflammation in PWH, existing data suggest that healthier dietary choices can positively alter the microbiota and diminish inflammation in PWH. This aligns with findings fr...
In fact, based on murine TB efficacy data with a recombinant auxothroph BCG vaccine expressing an African consensus HIV-1 clade A Gag immunogen (rBCG.HIVA) 5, 6, 7, 8, phase I clinical trials have been initiated in African neonates. The restriction of preclinical BCG-HIV immunogenicity ...
“VirusTaxonomy,”InFieldsVirology,2ndEd.,B.N.Fields,D.M.Knipeetal.,eds,RavenPress,NewYork,Chapter2,pp.9-36.MwauMI,CebereJ,SuttonP,etal.Ahumanimmunodeficiencyvirus1(HIV-1)cladeAvaccineinclinicaltrials:stimulationofHIV-specificT-cellresponsesbyDNAandrecombinantmodifiedvacciniavirusAnkara(MVA)vaccines...
and holds equity in Excision Biotherapeutics, a biotech start-up that has licensed the viral gene editing technology from Temple University for commercial development and clinical trials. T.H.B. and J.G. have equity in Excision Biotherapeutics and members of the Scientific Advisory Board. All othe...
AIDS Clinical Trials Group AIDS, 14 (1) (2000), pp. 11-21 View in ScopusGoogle Scholar 38 A Anema, E Mills, J Montaner, JS Brownstein, C Cooper Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis HIV Med, 9 (1) (2008), pp. 57-61 ...
The evaluation of the prevention efforts clearly indicates that they are insufficient to curb the epidemic: (1) although knowledge about AIDS has increased, it is not associated with appreciable behavioral changes; (2) condom sale has increased in urban areas but not in rural areas, where 70% ...